title: A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.
abstract: Heterologous prime-boost immunisation with RTS,S/AS02A and the poxvirus MVA-CS was evaluated in 18 healthy malaria-naïve subjects in Oxford. Both priming with RTS,S and boosting MVA-CS, and the reverse, were found to be safe and well tolerated. T cell responses as measured by IFN-gamma ex vivo ELISPOT were induced, but the responses were low to moderate in both groups, with heterologous boosting yielding only small increments in T cell immunogenicity and no increased antibody response. Protection against 3D7 Plasmodium falciparum sporozoite challenge 4 weeks after the final vaccination was equal for both regimens at 33% (95% C.I. 4.3-77.7%), with one subject remaining fully protected on rechallenge at 5 months.
authors.affiliation: Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK. susie.dunachie@ndm.ox.ac.uk
authors.forename: Susanna J
authors.initials: SJ
authors.lastname: Dunachie
authors.forename: Michael
authors.initials: M
authors.lastname: Walther
authors.forename: Jenni M
authors.initials: JM
authors.lastname: Vuola
authors.forename: Daniel P
authors.initials: DP
authors.lastname: Webster
authors.forename: Sheila M
authors.initials: SM
authors.lastname: Keating
authors.forename: Tamara
authors.initials: T
authors.lastname: Berthoud
authors.forename: Laura
authors.initials: L
authors.lastname: Andrews
authors.forename: Philip
authors.initials: P
authors.lastname: Bejon
authors.forename: Ian
authors.initials: I
authors.lastname: Poulton
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Butcher
authors.forename: Katherine
authors.initials: K
authors.lastname: Watkins
authors.forename: Robert E
authors.initials: RE
authors.lastname: Sinden
authors.forename: Amanda
authors.initials: A
authors.lastname: Leach
authors.forename: Philippe
authors.initials: P
authors.lastname: Moris
authors.forename: Nadia
authors.initials: N
authors.lastname: Tornieporth
authors.forename: Joerg
authors.initials: J
authors.lastname: Schneider
authors.forename: Filip
authors.initials: F
authors.lastname: Dubovsky
authors.forename: Eveline
authors.initials: E
authors.lastname: Tierney
authors.forename: Jack
authors.initials: J
authors.lastname: Williams
authors.forename: D Gray
authors.initials: DG
authors.lastname: Heppner
authors.forename: Sarah C
authors.initials: SC
authors.lastname: Gilbert
authors.forename: Joe
authors.initials: J
authors.lastname: Cohen
authors.forename: Adrian V S
authors.initials: AV
authors.lastname: Hill
mesh_terms: D000293:Adolescent; D000328:Adult; D000913:Antibodies, Protozoan / Q000097:blood; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007371:Interferon-gamma / Q000096:biosynthesis; D008288:Malaria / Q000276:immunology / Q000517:prevention & control*; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology; D014616:Vaccinia virus / Q000276:immunology*
chemical_list: D000913:Antibodies, Protozoan; D017780:Malaria Vaccines; C493155:RTS,S-AS02A vaccine; D007371:Interferon-gamma